Piper Sandler Increases IDEXX Laboratories (NASDAQ:IDXX) Price Target to $510.00

IDEXX Laboratories (NASDAQ:IDXX - Free Report) had its target price boosted by Piper Sandler from $435.00 to $510.00 in a report published on Monday,Benzinga reports. They currently have a neutral rating on the stock.

A number of other brokerages have also recently weighed in on IDXX. Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Leerink Partners started coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target for the company. Barclays increased their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Morgan Stanley reduced their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Finally, Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

IDEXX Laboratories Trading Up 0.7 %

Shares of NASDAQ IDXX traded up $3.04 during midday trading on Monday, hitting $460.39. The stock had a trading volume of 309,775 shares, compared to its average volume of 709,293. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories has a 1-year low of $398.50 and a 1-year high of $583.39. The company has a market capitalization of $37.70 billion, a price-to-earnings ratio of 43.15, a PEG ratio of 3.47 and a beta of 1.37. The company has a fifty day moving average price of $430.12 and a 200 day moving average price of $453.26.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,330 shares of company stock valued at $6,161,276. Insiders own 2.11% of the company's stock.

Institutional Trading of IDEXX Laboratories

Several institutional investors and hedge funds have recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the 3rd quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock worth $29,000 after purchasing an additional 57 shares during the period. Hurley Capital LLC acquired a new position in IDEXX Laboratories in the fourth quarter worth $29,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories during the fourth quarter valued at $30,000. Finally, Retirement Wealth Solutions LLC acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth $31,000. Institutional investors and hedge funds own 87.84% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.